Cited by 151Genetic Neurodegenerative DiseasesCoenzyme Q10 studies and effectsNeurological diseases and metabolism

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

Schilling, Gabriele, Coonfield, Michael L, Ross, Christopher A, Borchelt, David R·2001·Neuroscience Letters

Abstract

Huntington's disease (HD) is a progressive inherited neurodegenerative disorder, for which there is no effective therapy. The CARE-HD study, recently published, evaluated the ability of a combination of coenzyme Q10 (CoQ10) and remacemide hydrochloride (R) to ameliorate symptoms, which might arise from glutamate-mediated excitotoxicity and abnormalities in mitochondrial energy production. In this study, we examined the efficacy of CoQ10/R therapy on ameliorating the motor dysfunction and premature death of HD-N171-82Q transgenic mice. Motor performance, measured on the Rotarod, was specifically but transiently improved beginning 3 weeks after initiating the CoQ10/R therapy. Survival, however was not prolonged. Our findings suggest that further study of CoQ10/R in mouse models is warranted to investigate whether this therapeutic approach can ameliorate the symptoms of HD in early stages of the disease.

Integrity signals

Registry

Crossref · 10.1016/s0304-3940(01)02326-6

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CoQ10 and remacemide combination therapy observed significantly improved motor performance and increased survival in the R6/2 and N-171-82Q transgenic mouse models of HD.

    “Similarly, we and others, by using CoQ10 and remacemide (NMDA antagonist) combination therapy observed significantly improved motor performance and increased survival in the R6/2 and the N-171-82Q transgenic mouse models of HD151, 154.”

    From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [154]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R.
Affiliations
Johns Hopkins University (US)
Corresponding author
Schilling, Gabriele
Venue
Neuroscience Letters
Publisher
Elsevier BV
Published
2001-11
Volume
315
Issue
3
Pages
149-153
ISSN
0304-3940 (ISSN-L)
OpenAlex
W2084728929
Cited by
151
References
20
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 4 · 2014: 8 · 2013: 4 · 2012: 14
FWCI
4.67
Type
journal article
Language
en
Open access
closed
Locations
  • Neuroscience Letters (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
Huntington's disease, coenzyme Q10, motor impairment, rotarod performance, survival, glutamate excitotoxicity, mitochondrial energy production, neurodegeneration
MeSH terms
Huntingtin Protein, Acetamides, Animals, Antioxidants, Coenzymes, Drug Therapy, Combination, Huntington Disease, Mice, Transgenic, Motor Activity, Nerve Tissue Proteins, Nuclear Proteins, Peptide Fragments, Time Factors, Ubiquinone, Survival Analysis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review